Valsartan

Limits on what this shows

• Key negative/null findings: A third study, title "Valsartan improves mitochondrial function in hearts submitted to acute ischemia" (PMID 16055115, 2005), was identified by title and appears consistent with the same protective direction, but could not be independently opened for full-text verification in this review; it is named in the sources list with that flag and is not cited for any statistic here. No study located reports valsartan impairing mitochondrial function at any dose in any species.
• At-risk subgroups: None defined. Both verified studies used disease or stress models (renovascular hypertension, insulin resistance) in which valsartan's effect was to rescue an already-suppressed mitochondrial state, not a baseline effect in unstressed tissue.
• Dose and duration: 320 mg/day for 4 weeks in pigs (above the typical human ceiling of 320 mg/day but within the labeled maximum); 8 µM for 24 hours in vitro. Neither maps precisely onto standard human oral dosing, and no lower-dose or shorter-exposure data were located.

Regulatory status

Mitochondria, mitochondrial function, and mitochondrial toxicity are not named anywhere in the Diovan prescribing information.

Population evidence

None in humans. Tier B with valsartan in the cohort: study title "Valsartan Regulates Myocardial Autophagy and Mitochondrial Turnover in Experimental Hypertension," Hypertension 2014, PMID 24752430, doi 10.1161/HYPERTENSIONAHA.113.02151: domestic pigs with unilateral renovascular hypertension, valsartan 320 mg/day for 4 weeks after 6 weeks of established hypertension, n=7 per group, ex vivo myocardial analysis of autophagy markers, mitochondrial degradation and biogenesis markers, and respiratory-chain proteins. Untreated hypertension increased cellular autophagy and mitochondrial degradation and suppressed mitochondrial biogenesis; valsartan alleviated left ventricular hypertrophy, ameliorated autophagy and mitophagy, and increased mitochondrial biogenesis, an effect not matched by a conventional triple-drug regimen that lowered blood pressure similarly. Wyatt et al., "Valsartan Rescues Suppressed Mitochondrial Metabolism during Insulin Resistance in C2C12 Myotubes," Cell Biochem Funct 2024, doi 10.1002/cbf.4117, PMID 39243192: C2C12 mouse myotubes treated with valsartan 8 µM for 24 hours, with and without hyperinsulinemia-induced insulin resistance; oxygen consumption and extracellular acidification measured mitochondrial and glycolytic metabolism. Insulin resistance significantly reduced basal and peak mitochondrial function, which was rescued to control levels by concurrent valsartan, without substantial change in mitochondrial content or related gene expression; insulin sensitivity, glycolytic metabolism, and lipid content were unaffected by valsartan alone.

Mechanism

Plausible and consistently protective in the available data, though not established in humans. AT1-receptor blockade reduces angiotensin-II-driven mitochondrial stress and, in the pig model, is associated with increased mitochondrial biogenesis markers; the C2C12 study identifies valsartan as an inhibitor of branched-chain alpha-keto acid dehydrogenase kinase (BCKDK), a separate proposed route by which it could support myotube metabolism. There is no described route by which valsartan would impair oxidative phosphorylation directly: it is not extensively metabolized, does not clinically inhibit any CYP450 enzyme, and is largely excreted unchanged, so the conjugation-driven and reactive-metabolite routes to mitochondrial injury are absent by the label's own pharmacokinetic description.

Counter-evidence held on record

None found running the opposite direction; every mitochondrial finding independently verified for valsartan, in two different model systems, points the same protective way. The main limitation is that neither study used a human subject, and the pig study's dose exceeds typical human dosing on an absolute-mg basis. Do not say valsartan damages mitochondria; the animal and cell data say the opposite. Do not say valsartan is a mitochondrial therapy in humans; it has never been tested that way. No coenzyme Q10, carnitine, ribose, or other mitochondrial supplement recommendation follows from this entry, and none is made.

Limits on what this shows

• Key negative/null findings: None located that directly contradict the Yang 2007 direction. Two further Tier A human candidates were identified by title, "Reduction of QTc dispersion by the angiotensin II receptor blocker valsartan may be related to its anti-oxidative stress effect in patients with essential hypertension" (PMID 17541209) and "Effects of valsartan and amlodipine on oxidative stress in type 2 diabetic patients with hypertension: a randomized, multicenter study" (PMID 28490725, PMC5432799), both apparently consistent by title with a protective direction, but neither could be independently opened for full-text verification in this review; both are named in the sources list with that flag and neither is cited for any statistic in this entry. This entry therefore rests on one independently verified Tier A study, which is why it is held at orange with a single-study caveat rather than treated as a strongly replicated finding.
• At-risk subgroups: None defined by the available data. The Yang 2007 population was stage I–II hypertensive adults with no stated stratification by age, renal function, or baseline antioxidant status.
• Dose and duration: 80–160 mg once or twice daily, effect present by 12 weeks with measurements every 4 weeks; no data on shorter exposure or on whether the effect plateaus or continues to change beyond 12 weeks.

Regulatory status

Oxidative stress and antioxidant enzyme activity are not named anywhere in the Diovan prescribing information.

Population evidence

Yang HY, Kao P, Chen TH, Tomlinson B, Ko WC, Chan P. Effects of the angiotensin II type 1 receptor antagonist valsartan on the expression of superoxide dismutase in hypertensive patients. J Clin Pharmacol 2007. PMID 17322151. Randomized, double-blind, placebo-controlled study, 48 stage I–II hypertensive subjects, valsartan titrated to 80–160 mg once or twice daily versus placebo, follow-up every 4 weeks over 12 weeks. Baseline erythrocyte superoxide dismutase (SOD) activity in these hypertensive patients was more than double that of healthy controls. After 12 weeks, the valsartan group showed significant reductions in both SOD activity and SOD-mRNA expression in polymorphonuclear leukocytes, while the placebo group showed no change; the drug also showed concentration-dependent inhibition of reactive oxygen species generation. The authors interpreted the falling, previously-elevated SOD activity as evidence of reduced oxidative stress rather than of an antioxidant deficit.

Mechanism

Named and consistent with the well-established RAAS-oxidative stress pathway: angiotensin II acting on the AT1 receptor drives NADPH oxidase activity and reactive oxygen species generation; blocking that receptor lowers the reactive oxygen species load, which plausibly reduces the compensatory upregulation of SOD seen at baseline in untreated hypertension.

Counter-evidence held on record

None found running the opposite direction. The main limitation on record is evidentiary rather than contradictory: this dossier could independently verify only one of three Tier A human candidates identified in the search, so the finding is real and drug-specific but rests on a single confirmed trial rather than a replicated one. Do not state that valsartan causes oxidative stress; the verified human data run the opposite way. Do not state that valsartan is an antioxidant therapy or that it treats oxidative stress. Above all, do not convert the falling SOD activity into a selenium, zinc, or antioxidant-nutrient deficiency, or into a reason to supplement any of them; none was measured in this study, and this dossier makes no dosing recommendation for a nutrient at this tier.

Limits on what this shows

• Key negative/null findings: A search for antihypertensive-drug effects on copper status in an animal model ("The influence of selected antihypertensive drugs on zinc, copper, and iron status in spontaneously hypertensive rats," Eur J Pharmacol 2014) found the study tested perindopril, metoprolol, indapamide, and amlodipine, and explicitly did not include valsartan or any ARB. This closes off even a Tier C class-extrapolation route for copper via that study; it is cited to document that the search was made and came back negative for this drug class, not as supporting evidence.
• At-risk subgroups: None definable. There is no valsartan copper dataset, human or animal, from which to identify one.
• Dose and duration: Not applicable. The available valsartan-copper chemistry is a synthesized coordination compound, not a dosed exposure, and carries no dose or duration that maps to a patient.

Regulatory status

Copper is not named anywhere in the Diovan prescribing information.

Population evidence

None at any tier, in any species. A targeted search for valsartan or ARB-class drugs together with copper status, serum copper, or copper metabolism returned no biological status study. Tier B with valsartan in the cohort, synthetic chemistry only: Etcheverry SB et al., "Dinuclear copper(II) complexes with valsartan. Synthesis, characterization and cytotoxicity," J Inorg Biochem 2012;106(1):25–33. Valsartan was used as a ligand to synthesize dinuclear copper(II) coordination complexes, characterized structurally and tested for cytotoxicity, a line of anticancer-chemistry research unrelated to nutrient status. A separate materials-science paper, "Synthesis and Use of Valsartan Metal Complexes as Media for Carbon Dioxide Storage," Materials 2020;13(5):1183 (doi 10.3390/ma13051183), synthesized valsartan complexes with tin(IV), nickel(II), and magnesium(II) for gas-storage applications; it did not include a copper or an iron complex, and is cited here to document a negative search result, not as supporting evidence.

Mechanism

Weaker than the zinc entry in this dossier, and weaker than lisinopril's analogous copper entry in the companion ACE-inhibitor dossier. ACE is a zinc metalloenzyme, which at least gives zinc claims for that class a target-level rationale; the AT1 receptor that valsartan blocks is not a copper-dependent or copper-binding target, so there is no equivalent structural rationale here at all. What remains is generic coordination chemistry demonstrated in synthesized, purpose-built complexes, not a description of what happens to endogenous copper when a person takes the drug orally.

Counter-evidence held on record

None specific to valsartan and copper exists to hold, which is itself part of the finding: no study, in either direction, has looked at copper status on this drug. The synthesized copper-valsartan complexes described above are engineered research compounds built for cytotoxicity or materials-science purposes and must not be read as evidence about the drug as prescribed. Do not state or imply that valsartan depletes copper. The accurate framing is that copper status has never been measured on this drug, that the only copper chemistry demonstrated for valsartan is a laboratory-synthesized compound built for an unrelated research purpose, and that no consumer source reviewed for this dossier makes a copper claim for valsartan or for ARBs as a class. No copper testing and no copper supplement is recommended by this dossier.

Limits on what this shows

• Why no grade: Yellow requires either mechanistic plausibility at Tier B or class extrapolation at Tier C. Neither condition is met: no ARB, valsartan or otherwise, has been shown to alter serum iron, ferritin, transferrin saturation, or hepcidin, and no valsartan-specific iron-chelation or iron-binding chemistry was located despite a dedicated search (the one relevant metal-complex paper found synthesized tin, nickel, and magnesium complexes of valsartan, explicitly not iron). White requires a circulating claim to rebut; the consumer sources reviewed for this dossier's original and expanded claim audits list calcium, carnitine, chloride, CoQ10, magnesium, potassium, sodium, and zinc for this drug class, and none lists iron. The category therefore sits outside all four tiers, and this dossier prints it rather than dropping it.
• What would fill it: A study directly measuring serum iron, ferritin, transferrin saturation, or hepcidin in a defined valsartan-treated human or animal cohort, with valsartan named as a study arm rather than pooled into "ARBs" or "antihypertensives." Failing that, an in vitro iron-chelation or iron-binding chemistry study using valsartan itself, analogous to the copper complexes already synthesized, would at least establish a Tier B mechanistic basis for a yellow grade.

What was searched

Targeted searches for valsartan or ARB-class drugs together with iron status, serum iron, ferritin, hepcidin, and iron chelation; a search for antihypertensive-drug effects on iron status in spontaneously hypertensive rats (which tested perindopril, metoprolol, indapamide, and amlodipine, explicitly not valsartan or any ARB); and a search for valsartan-metal complex chemistry (which found copper, tin, nickel, and magnesium complexes, not iron).

The one near-miss, and why it doesn't clear the bar

The FDA label records that one valsartan-treated patient discontinued therapy for microcytic anemia, a red-cell pattern classically associated with iron deficiency in general medicine. This is a single, uncontrolled adverse-event report in a large trial database, with no serum iron, ferritin, or transferrin saturation reported alongside it, and no comparator. Per this dossier's rules, a clinical outcome (anemia, of any morphology) is not a nutrient-deficiency finding unless the nutrient itself was measured; it was not. This single case is recorded under the oxygen carriage entry above, where the rest of the hematologic evidence lives, and is deliberately not promoted into a graded iron entry on its own.

Human cohort context

The oxygen carriage entry's own drug-specific study, Durmus 2005, scheduled hemoglobin, hematocrit, and standard renal chemistries in its 22 CKD patients but did not report iron parameters at all, so it neither supports nor refutes an iron-status claim; it is simply silent on iron.

Counter-evidence held on record

There is none to hold, which is the finding. Nothing supports an iron-depletion claim for valsartan and nothing rules one out. This is the highest-risk misreading available in this dossier, because the oxygen carriage entry immediately above it invites exactly the wrong inference. Say plainly that this is not established as iron deficiency, that iron levels have not been shown to fall on this drug, and that a falling hemoglobin on valsartan is a reason to have the anemia worked up, never a reason to start iron on assumption. Absence of evidence is not evidence of safety, so do not publish "valsartan does not affect iron" either; say only that this has not been studied.

Limits on what this shows

• Key negative/null findings: No human valsartan microbiome study of any kind was located, so there is no null (or positive) human result to weigh. The systematic review's framing of the Qi 2021 result as atypical for the ARB class functions as a caution against generalizing this single rat study, rather than as a direct contradiction of it.
• Confounding by indication: Directly addressed by the study design: the primary comparison was valsartan-treated SHR versus untreated SHR, the same hypertensive genotype and strain, which controls for the disease state itself being the driver of any microbiome difference. The larger diversity gap was between SHR and normotensive WKY controls (192 OTUs) rather than between treated and untreated SHR (10 OTUs), which is consistent with hypertension itself, not valsartan, being the dominant driver of the baseline microbiome difference, with valsartan contributing a smaller additional shift on top of it.
• At-risk subgroups: None definable from a single rat study. No human data exist from which to identify a subgroup.
• Dose and duration: 7.4 mg/kg/day intragastrically for 6 weeks in rats. This is a gavage-bolus route rather than the dietary administration used in other ARB microbiome studies reviewed by the 2025 systematic review, a methodological difference the review itself raises as a possible source of valsartan's atypical result. No human dose-equivalent data exist.

Regulatory status

Gut microbiota, intestinal flora, and microbiome are not named anywhere in the Diovan prescribing information.

Population evidence

None in humans. Tier B with valsartan in the cohort: Qi YZ, Jiang YH, Jiang LY, Shao LL, Yang XS, Yang CH. "An Insight Into Intestinal Microbiota of Spontaneously Hypertensive Rats After Valsartan Administration." 2021, PMID 33994888, doi 10.1177/15593258211011342. Spontaneously hypertensive rats (SHR), 8–9 weeks old, versus normotensive Wistar-Kyoto (WKY) controls; valsartan 7.4 mg/kg/day by intragastric administration for 6 weeks, against untreated SHR and WKY groups receiving normal saline. Alpha-diversity (operational taxonomic units, phylogenetic diversity) fell in valsartan-treated SHR versus both WKY controls (192 fewer unique OTUs) and untreated SHR (10 fewer unique OTUs); beta-diversity (PCoA) also shifted. Lactobacillus abundance rose significantly; Actinobacteria remained over-represented and Cyanobacteria remained depleted despite treatment; the Firmicutes:Bacteroidetes ratio, elevated in untreated SHR, stayed elevated on valsartan. Short-chain fatty acid output by GC-MS showed decreased isobutyric and isovaleric acid with valsartan, no significant change in acetic, propionic, valeric, or caproic acid. The study authors describe valsartan as showing "some effect similar to antibiotics on intestinal microbiota."

Mechanism

Not established. No direct antimicrobial activity of valsartan against gut commensals has been demonstrated; the reduced diversity could reflect a direct luminal drug effect, an indirect effect of blood-pressure reduction or altered gut perfusion, or the drug's unabsorbed fraction (roughly 75% of an oral dose, given about 25% bioavailability) reaching the colon. A 2025 systematic review of ACE inhibitor and ARB effects on the gut microbiome ( Front Endocrinol 2025, doi 10.3389/fendo.2025.1685424) discusses the Qi 2021 valsartan finding specifically and flags it as atypical relative to other ARBs reviewed: valsartan showed decreased diversity in both directions (alpha and beta) alongside only a partial anti-inflammatory signal (reduced C-reactive protein but no improvement in gut barrier integrity), and plasma angiotensin II remained persistently elevated during treatment in that study, suggesting incomplete RAS inhibition. The review authors note valsartan's comparatively lower bioavailability and its intragastric (rather than dietary) route of administration in this particular study as possible confounders, and call for validating whether any gut-protective effect is a true class effect of ARBs.

Counter-evidence held on record

The 2025 systematic review is itself the counter-evidence held on record: it treats the Qi 2021 valsartan result as an outlier among ARB microbiome studies rather than as a settled class effect, and it explicitly raises the study's unusual dosing route as a plausible confound. No study of any kind reports valsartan improving or leaving gut microbiota unchanged, so this is not a case of contradicting evidence, only of a single, flagged, unreplicated result. Do not state that valsartan disrupts the gut microbiome as an established human effect; the only evidence is one rat study, flagged by a systematic review as atypical for its own drug class. Do not publish a probiotic or gut-health supplement prompt attached to this drug on the strength of this entry. If anything surfaces to a reader, it should say only that this has been studied once, in animals, with a result that needs confirmation.

Limits on what this shows

• Key negative/null findings: Durmus 2005 is the key finding bounding this entry: it is a valsartan-specific, Tier A null on the functional hemoglobin/hematocrit endpoint itself, recorded in the same cohort and at the same timepoint that erythropoietin fell significantly and progressively. This drug-specific dissociation between erythropoietin and hemoglobin is the main reason this entry is held at orange rather than red.
• At-risk subgroups: Defined by the label itself: the 0.4%/0.8% figures describe a minority of the general trial population; the label does not report a CKD-specific stratification for this finding, and the one CKD-specific study (Durmus) paradoxically found no hemoglobin change in that population. Patients with another cause of anemia, per the same general pattern documented for ACE inhibitors, remain the most plausible at-risk group, though this has not been tested directly for valsartan.
• Dose and duration: The label finding is pooled across the therapeutic range in controlled trials and is not dose-stratified. Durmus used 80 mg/day for 90 days. The ESPECIAL olmesartan finding used 40 mg/day for 8 weeks.

Regulatory status

FDA label (Diovan, 2017 revision), Adverse Reactions, Clinical Laboratory Test Findings, verbatim: "Greater than 20% decreases in hemoglobin and hematocrit were observed in 0.4% and 0.8%, respectively, of Diovan patients, compared with 0.1% and 0.1% in placebo-treated patients." The same table records that one valsartan patient discontinued treatment for microcytic anemia, a single uncontrolled case with no iron parameters reported; it is addressed under the Iron ungraded entry below and is not counted as evidence here.

Population evidence

Two independent Tier A sources with valsartan in the cohort. (1) The label finding above. (2) Durmus et al., Int J Clin Pract 2005;59(10) (doi 10.1111/j.1742-1241.2005.00606.x, PMID 16115171): 22 stage III-IV chronic kidney disease patients (mean age 56.8±8.9), valsartan 80 mg/day begun after a 3-week washout, erythropoietin measured at baseline, 3, 6 and 90 days. Erythropoietin fell significantly at every timepoint: 19.6±24.0 to 13.8±8.5 at day 3 (p=.010), 12.1±7.6 at day 6 (p=.009), 8.3±5.4 at day 90 (p=.007). At day 90, "no significant change was observed in terms of hgb, htc, serum BUN, creatinine, uric acid, potassium, and GFR values." The authors concluded valsartan did not decrease hemoglobin despite the erythropoietin fall, and suggested ARBs may be preferable to ACE inhibitors in CKD on that basis. Supporting Tier C, class-level, olmesartan not valsartan: post-hoc analysis of the ESPECIAL trial, PLoS ONE 2015;10(6):e0128632 (doi 10.1371/journal.pone.0128632), 245 non-diabetic hypertensive patients with albuminuria, olmesartan 40 mg/day for 8 weeks, hemoglobin fell from 13.9±1.7 to 13.6±1.7 g/dL, and the magnitude of the hemoglobin fall correlated with albuminuria reduction independent of erythropoietin change or renal function decline (adjusted OR 1.76, 95% CI 1.21–2.56, p=.003), framed by the authors as a possible surrogate marker of ARB efficacy rather than a harm signal.

Mechanism

Named. AT1-receptor blockade removes angiotensin II's facilitation of erythropoiesis at the erythroid progenitor level, the same receptor-level pathway established for ACE inhibitors. Cole et al., J Clin Invest 2000;106(11):1391–1398 (PMID 11104792): ACE-knockout mice are anemic despite elevated erythropoietin, with hematocrit restored by angiotensin II infusion; no ACE inhibitor or ARB was administered in that study, and it is cited here as a mechanism reference only, applicable to any RAAS blockade rather than to valsartan specifically.

Counter-evidence held on record

Durmus 2005 is itself the strongest counter-evidence on record: a valsartan-specific, Tier A study that measured both the proposed mechanism (erythropoietin, which fell) and the proposed outcome (hemoglobin/hematocrit, which did not move) in the same 22 patients over 90 days. A drug-specific renal transplant hematocrit study was located in search results but could not be independently opened for verification and is named in the sources list with that flag rather than cited for any statistic here. Never present this as iron deficiency, and never as a reason to start an iron supplement or eat for iron. The one case in the label of a patient discontinuing for microcytic anemia is a single uncontrolled report with no iron studies attached to it; it is not evidence that valsartan depletes iron. The correct consumer framing is that a small drop in hemoglobin is uncommon and usually unimportant, that it matters mainly if another cause of anemia is present, and that new or worsening anemia is a conversation with the prescriber rather than a supplement decision.

Limits on what this shows

• Why no grade: Yellow requires either mechanistic plausibility at Tier B or class extrapolation at Tier C, specific to the parameter being graded. A dedicated search for valsartan together with ATP content, cellular ATP, high-energy phosphates, or 31 P spectroscopy found no study measuring tissue ATP or phosphate levels in a valsartan-exposed system at any tier. The two mitochondrial studies used for the yellow-tier mitochondrial burden entry (the pig autophagy/biogenesis study and the C2C12 myotube oxygen-consumption study) measure respiratory capacity and mitochondrial turnover, not ATP content itself, and this dossier's overlap-control rule (see the overlap map below) assigns respirometry findings to mitochondrial burden only, to avoid the same evidence silently generating two grades. White requires a circulating claim specifically alleging that valsartan depletes ATP or cellular energy; no consumer source reviewed for this dossier makes that specific claim. A related but distinct claim, that ARBs including this class may deplete coenzyme Q10, already appears in this dossier's original Fails Verification table (see below) and was already rebutted there before this expansion; it is a supplement-focused claim about a cofactor, not a status claim about ATP itself, and its pre-existing white-tier disposition does not change the ungraded status of ATP production as a parameter.
• What would fill it: A 31 P nuclear magnetic resonance study or a direct biochemical ATP assay in a valsartan-treated tissue, human or animal, at a clinically relevant dose, ideally under a metabolic stress (ischemia, exercise) that would expose any latent energetic deficit.

What was searched

Targeted searches for valsartan together with ATP content, cellular ATP, 31 P nuclear magnetic resonance, and high-energy phosphate metabolism, in rat, mouse, and human tissue; none returned a study measuring the parameter directly for this drug.

Adjacent evidence, and why it isn't counted here

The pig myocardial study (mitochondrial burden entry) measured autophagy, mitophagy, and biogenesis markers and respiratory-chain protein expression, not ATP content. The C2C12 myotube study (also mitochondrial burden) measured oxygen consumption rate, a respiratory-capacity proxy, not direct ATP quantification. Both are real, valsartan-specific, Tier B findings, and both point in a protective direction, but neither satisfies the specific evidentiary bar this dossier sets for the ATP production category, which is reserved for direct tissue ATP or phosphate measurement.

Counter-evidence held on record

There is none to hold, which is the finding. The adjacent mitochondrial-capacity evidence, held under the mitochondrial burden entry, is uniformly protective in direction, which weighs generally against expecting a hidden ATP deficit, but it is not a substitute for a direct measurement and is not cited as one here. Do not tell readers valsartan lowers their cellular energy production; it has never been measured. Do not present the pre-existing coenzyme Q10 rebuttal (below) as if it settled the ATP question; it addresses a different, supplement-focused consumer claim. If anything surfaces at all here, it should say only that tissue energy production has not been studied on this drug.